Acrivon Therapeutics Inc
ACRV1.300USD
+0.040+3.18%
交易中 （美東）報價延遲15分鐘
40.76M總市值
虧損本益比TTM
關於 Acrivon Therapeutics Inc 公司
Acrivon Therapeutics, Inc. 是一家臨牀階段生物製藥公司，致力於開發精準腫瘤藥物。該公司利用其精準醫療平臺 Acrivon Predictive Precision Proteomics (AP3) 開發其腫瘤候選藥物管線。其主要候選藥物 ACR-368 是一種選擇性小分子抑制劑，在完整細胞中分別以低於個位數 nM 和個位數 nM 的效力靶向 CHK1 和 CHK2，目前正處於一項可能註冊的 2 期臨牀試驗中，涉及多種實體腫瘤類型。利用其 AP3 平臺，該公司開發了一種針對 ACR-368 的預測性 OncoSignature 測試，稱爲 ACR-368 OncoSignature，可以預測患者對 ACR-368 單藥治療的反應，從而大幅提高臨牀總體緩解率 (ORR)，並有可能加快藥物開發。其臨牀前項目 ACR-2316 正在 IND 支持研究中取得進展。它是一種新型的雙重 WEE1 和 PKMYT1 抑制劑小分子開發候選藥物。
公司簡介
公司代碼ACRV
公司名稱Acrivon Therapeutics Inc
上市日期Nov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
員工數量75
證券類型Ordinary Share
年結日Nov 15
公司地址480 Arsenal Way, Suite 100
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02472
電話16172078979
網址https://acrivon.com/
公司代碼ACRV
上市日期Nov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mrs. Mary-Alice Miller, J.D.
Mrs. Mary-Alice Miller, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月1日 週五
更新時間: 8月1日 週五
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
持股股東
持股股東
佔比
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
股東類型
持股股東
佔比
Venture Capital
26.60%
Hedge Fund
13.15%
Corporation
12.27%
Individual Investor
8.56%
Investment Advisor
7.97%
Investment Advisor/Hedge Fund
6.91%
Research Firm
0.36%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
24.12%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
142
23.71M
75.61%
-5.03M
2025Q1
146
29.35M
93.70%
-2.39M
2024Q4
141
30.19M
96.96%
-1.30M
2024Q3
129
30.21M
97.90%
-1.16M
2024Q2
124
30.86M
100.26%
+1.75M
2024Q1
110
20.99M
93.28%
+95.57K
2023Q4
96
21.08M
95.04%
+130.06K
2023Q3
91
21.13M
95.90%
+687.39K
2023Q2
85
20.62M
94.10%
+177.16K
2023Q1
71
22.16M
102.70%
+6.28M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
8.34M
26.6%
--
--
Mar 31, 2025
Chione, Ltd.
3.85M
12.27%
--
--
Jun 30, 2024
Blume-Jensen (Peter)
2.21M
7.04%
-79.67K
-3.49%
May 21, 2025
Sands Capital Ventures LLC
2.12M
6.77%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.90M
6.05%
-224.13K
-10.57%
Mar 31, 2025
Wellington Management Company, LLP
888.13K
2.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
844.91K
2.69%
-5.84K
-0.69%
Mar 31, 2025
The Vanguard Group, Inc.
674.79K
2.15%
+3.17K
+0.47%
Mar 31, 2025
Marshall Wace LLP
450.39K
1.44%
-147.40K
-24.66%
Mar 31, 2025
Acorn Capital Advisors, LLC
405.24K
1.29%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
iShares Russell 2000 ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
iShares Biotechnology ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Global X Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
